Consolidation cetuximab after concurrent triplet radiochemotherapy+cetuximab in patients with advanced head and neck cancer: A randomized phase II study.

Publikation

Consolidation cetuximab after concurrent triplet radiochemotherapy+cetuximab in patients with advanced head and neck cancer: A randomized phase II study.

Wissenschaftlicher Artikel/Review - 12.06.2020

Riesterer Oliver, Pruschy Martin, Bender Sabine, Sharma Ashish, Bogowicz Marta, Tanadini-Lang Stephanie, Stieb Sonja, Bertogg Kaja, Weber Sandra, Ikenberg Kristian, Huber Gerhard, Schmid Stephan, Bredell Marius, Veit-Haibach Patrick, Rordorf Tamara, Held Ulrike, Glanzmann Christoph, Studer Gabriela

Zitation

Riesterer O, Pruschy M, Bender S, Sharma A, Bogowicz M, Tanadini-Lang S, Stieb S, Bertogg K, Weber S, Ikenberg K, Huber G, Schmid S, Bredell M, Veit-Haibach P, Rordorf T, Held U, Glanzmann C, Studer G. Consolidation cetuximab after concurrent triplet radiochemotherapy+cetuximab in patients with advanced head and neck cancer: A randomized phase II study. Radiother Oncol 2020; 150:62-69.

Art

Wissenschaftlicher Artikel/Review (Englisch)

Zeitschrift

Radiother Oncol 2020; 150

Veröffentlichungsdatum

12.06.2020

eISSN (Online)

1879-0887

Seiten

62-69

Kurzbeschreibung/Zielsetzung

Preclinical data suggest that cetuximab should be continued after end of concurrent radiotherapy+cetuximab due to its efficacy against residual tumor cells in the irradiated tumor bed. Based on this concept the phase II add-on cetuximab (AOC) study was designed.